{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:41:35Z","timestamp":1793198495785,"version":"4.5.0"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In Denmark, cost savings motivate mandatory biosimilar switches. In 2018, patients switched from originator to biosimilar adalimumab, that is, to GP2017 in Eastern and to SB5 in Western Denmark. However, concerns were raised about additional costs covering, that is, an increased number of outpatient visits due to patient education, treatment monitoring, and patient concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To investigate whether the switch led to increased total healthcare costs, defined as costs related to in- and outpatient contacts in hospitals and the primary sector and use of prescription medicine (excluding biological treatment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Observational cohort study with geographical cluster pseudo-randomization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with rheumatoid arthritis, psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA), who switched were identified in the nationwide DANBIO registry. Total healthcare costs 9\u2009months before and after the switch were captured from the National Patient and Prescription registries. The difference between pre- and post-switch costs was estimated by a generalized estimation equations (GEE) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 1316 patients switched to GP2017 ( n\u2009=\u2009621) or SB5 ( n\u2009=\u2009695). Total healthcare costs were mainly driven by hospital costs. The monthly fluctuations of hospital costs 9\u2009months before and after the switch were largely similar or decreased. In the adjusted analyses (GEE), hospital costs decreased after the switch (by approximately 15%) for GP2017 switchers, especially PsA (estimate\u2009=\u20090.83; 95% CI 0.75\u20130.92) and AxSpA patients (estimate\u2009=\u20090.85; 0.77\u20130.93), with no significant changes for SB5 switchers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We found no increase in total healthcare costs in 9\u2009months following a nationwide mandatory adalimumab originator to biosimilar switch. Our findings were strengthened by similar results for GP2017 and SB5.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x241289391","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:13:56Z","timestamp":1729113236000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in &gt;1300 inflammatory arthritis patients"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-7927","authenticated-orcid":false,"given":"Hafsah","family":"Nabi","sequence":"first","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Valdemar Hansens Vej 17, Glostrup 2600, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Ibsen","sequence":"additional","affiliation":[{"name":"i2minds, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ibsen","sequence":"additional","affiliation":[{"name":"i2minds, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Kjellberg","sequence":"additional","affiliation":[{"name":"The Danish Centre for Social Science Research, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[{"name":"DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"bibr1-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex277"},{"key":"bibr2-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"bibr3-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000900"},{"key":"bibr4-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1002\/art.40336"},{"issue":"6","key":"bibr5-1759720X241289391","first-page":"914","volume":"77","author":"Cohen SB","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"bibr6-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2046-0"},{"key":"bibr7-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0769-6"},{"key":"bibr8-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16890"},{"key":"bibr9-1759720X241289391","unstructured":"Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU, www.ema.europa.eu\/contact (2022, accessed 16 September 2024)."},{"key":"bibr10-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211937"},{"key":"bibr11-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"bibr12-1759720X241289391","unstructured":"Troein P, Newton M, Scott K. The impact of biosimilar competition in Europe, https:\/\/ec.europa.eu\/health\/system\/files\/2021-01\/biosimilar_competition_en_0.pdf (2020, accessed 16 September 2024)."},{"key":"bibr13-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"key":"bibr14-1759720X241289391","unstructured":"Medicinr\u00e5det. Implementation of biosimilar Adalimumab, Denmark [Internet], https:\/\/medicinraadet.dk\/media\/svab0lxx\/medicinraadets-vurdering-af-ibrugtagning-af-biosimilaer-adalimumab-version-10_adlegacy.pdf (2018, accessed 16 September 2024)."},{"key":"bibr15-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02765-3"},{"key":"bibr16-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"issue":"11","key":"bibr17-1759720X241289391","first-page":"1400","volume":"80","author":"Nabi H","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"bibr18-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0338"},{"key":"bibr19-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01951-z"},{"key":"bibr20-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0306-1"},{"key":"bibr21-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00213-8"},{"key":"bibr22-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0085-z"},{"key":"bibr23-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S141438"},{"key":"bibr24-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq309"},{"key":"bibr25-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"bibr26-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810394718"},{"key":"bibr27-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37587"},{"key":"bibr28-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"bibr29-1759720X241289391","unstructured":"DRG-takster 2019\u2014Sundhedsdatastyrelsen, https:\/\/sundhedsdatastyrelsen.dk\/da\/afregning-og-finansiering\/takster-drg\/takster-2019 (2019, accessed 16 September 2024)."},{"key":"bibr30-1759720X241289391","unstructured":"Sundhedsdatastyrelsen. Datakvalitetsrapport om LPR 2019-overgangen fra LPR2 til LPR3, https:\/\/sundhedsdatastyrelsen.dk\/da\/registre-og-services\/om-de-nationale-sundhedsregistre\/sygdomme-laegemidler-og-behandlinger\/landspatientregisteret\/landspatientregisteret-moderniseres (2020, accessed 16 September 2024)."},{"key":"bibr31-1759720X241289391","unstructured":"Overblik over anmeldelsespligten | De Videnskabsetiske Komit\u00e9er, https:\/\/videnskabsetik.dk\/ansoegning-til-etisk-komite\/overblik-over-anmeldelsespligten (2024, accessed 16 September 2024)."},{"key":"bibr32-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2003.10.005"},{"issue":"1","key":"bibr33-1759720X241289391","first-page":"303728","volume":"2014","author":"Wang M","year":"2014","journal-title":"Adv Stat"},{"key":"bibr34-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209166"},{"key":"bibr35-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1188368"},{"key":"bibr36-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"bibr37-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00998-3"},{"key":"bibr38-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1652183"},{"key":"bibr39-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001016"},{"key":"bibr40-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000710"},{"issue":"1","key":"bibr41-1759720X241289391","first-page":"97","volume":"37","author":"Gibofsky A","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"bibr42-1759720X241289391","first-page":"102","volume":"25","author":"Leonard E","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr43-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04576-7"},{"key":"bibr44-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1002\/art.40324"},{"key":"bibr45-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00190-7"},{"key":"bibr46-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.10.952"},{"key":"bibr47-1759720X241289391","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.02.003"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X241289391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X241289391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X241289391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:39:48Z","timestamp":1777588788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X241289391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":47,"alternative-id":["10.1177\/1759720X241289391"],"URL":"https:\/\/doi.org\/10.1177\/1759720x241289391","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"1759720X241289391"}}